Compare SAM & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAM | RAPP |
|---|---|---|
| Founded | 1984 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 1996 | 2024 |
| Metric | SAM | RAPP |
|---|---|---|
| Price | $182.40 | $46.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $233.70 | $48.50 |
| AVG Volume (30 Days) | ★ 297.8K | 293.5K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.45 | 24.34 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,964,994,000.00 | N/A |
| Revenue This Year | $1.02 | N/A |
| Revenue Next Year | $1.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $158.68 | $13.86 |
| 52 Week High | $264.46 | $48.00 |
| Indicator | SAM | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 63.70 |
| Support Level | $166.11 | $38.95 |
| Resistance Level | $188.90 | N/A |
| Average True Range (ATR) | 6.47 | 2.24 |
| MACD | 0.41 | 0.40 |
| Stochastic Oscillator | 69.17 | 77.45 |
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.